A detailed history of Advisory Research Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Advisory Research Inc holds 55,419 shares of ABBV stock, worth $9.93 Million. This represents 2.14% of its overall portfolio holdings.

Number of Shares
55,419
Previous 56,645 2.16%
Holding current value
$9.93 Million
Previous $9.72 Million 12.65%
% of portfolio
2.14%
Previous 1.95%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$163.84 - $199.33 $200,867 - $244,378
-1,226 Reduced 2.16%
55,419 $10.9 Million
Q2 2024

Aug 13, 2024

BUY
$154.79 - $180.76 $502,293 - $586,566
3,245 Added 6.08%
56,645 $9.72 Million
Q1 2024

May 14, 2024

BUY
$159.82 - $182.1 $200,094 - $227,989
1,252 Added 2.4%
53,400 $9.72 Million
Q4 2023

Feb 13, 2024

BUY
$137.6 - $154.97 $657,040 - $739,981
4,775 Added 10.08%
52,148 $8.08 Million
Q3 2023

Nov 13, 2023

SELL
$133.59 - $154.65 $1 Million - $1.16 Million
-7,522 Reduced 13.7%
47,373 $7.06 Million
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $318,289 - $396,089
-2,402 Reduced 4.19%
54,895 $7.4 Million
Q1 2023

May 12, 2023

SELL
$144.61 - $166.54 $8 Million - $9.22 Million
-55,344 Reduced 49.13%
57,297 $9.13 Million
Q4 2022

Feb 13, 2023

SELL
$138.31 - $165.87 $115,212 - $138,169
-833 Reduced 0.73%
112,641 $18.2 Million
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $8.62 Million - $9.89 Million
-64,236 Reduced 36.15%
113,474 $15.2 Million
Q2 2022

Aug 17, 2022

BUY
$137.62 - $174.96 $278,130 - $353,594
2,021 Added 1.15%
177,710 $27.2 Million
Q1 2022

May 16, 2022

SELL
$131.98 - $163.75 $1.17 Million - $1.45 Million
-8,839 Reduced 4.79%
175,689 $28.5 Million
Q4 2021

Feb 11, 2022

SELL
$107.43 - $135.93 $1.96 Million - $2.48 Million
-18,226 Reduced 8.99%
184,528 $25 Million
Q3 2021

Nov 12, 2021

SELL
$106.4 - $120.78 $156,088 - $177,184
-1,467 Reduced 0.72%
202,754 $21.9 Million
Q2 2021

Aug 16, 2021

BUY
$105.21 - $117.21 $244,613 - $272,513
2,325 Added 1.15%
204,221 $23 Million
Q1 2021

May 12, 2021

BUY
$102.3 - $112.62 $4.74 Million - $5.21 Million
46,298 Added 29.75%
201,896 $21.8 Million
Q4 2020

Feb 12, 2021

SELL
$80.49 - $108.67 $489,218 - $660,496
-6,078 Reduced 3.76%
155,598 $16.7 Million
Q3 2020

Nov 12, 2020

SELL
$85.91 - $100.83 $1 Million - $1.18 Million
-11,694 Reduced 6.75%
161,676 $14.2 Million
Q2 2020

Aug 13, 2020

BUY
$73.37 - $98.18 $12.7 Million - $17 Million
173,370 New
173,370 $17 Million
Q1 2019

May 15, 2019

SELL
$77.14 - $90.79 $596,137 - $701,625
-7,728 Closed
0 $0
Q4 2018

Feb 13, 2019

SELL
$77.85 - $96.01 $9.94 Million - $12.3 Million
-127,618 Reduced 94.29%
7,728 $712,000
Q3 2018

Nov 13, 2018

SELL
$88.91 - $98.84 $588,406 - $654,123
-6,618 Reduced 4.66%
135,346 $12.8 Million
Q2 2018

Aug 14, 2018

BUY
$89.78 - $106.23 $114,379 - $135,337
1,274 Added 0.91%
141,964 $13.2 Million
Q1 2018

May 15, 2018

BUY
$92.01 - $123.21 $373,100 - $499,616
4,055 Added 2.97%
140,690 $13.3 Million
Q4 2017

Feb 08, 2018

BUY
$89.56 - $98.21 $269,575 - $295,612
3,010 Added 2.25%
136,635 $13.2 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $9.33 Million - $11.9 Million
133,625
133,625 $11.9 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $317B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Advisory Research Inc Portfolio

Follow Advisory Research Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

News

Stay updated on Advisory Research Inc with notifications on news.